Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Stockspawkon Aug 16, 2019 8:24am

126 Views

Post# 30035652

RE:RE:RE:RE:RE:RE:RE:Easy Peasy for private placement shares

it will not go back down to 30 40 cents thats for sure. It will also be higher than 70 80 cents. These results will pop the stock up large from where we are now. We most likely will see 60-70 cents pre results to be honest. Many NR's before results are what the company will do to draw attention to this before top line read out,

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!